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Abstract
Asthma is a chronic inflammatory disease characterised by airways remodelling. In mouse models IL-9 and IL-13 have been
implicated in airways remodelling including mucus hypersecretion and goblet cell hyperplasia. Their role, especially that of
IL-9, has been much less studied in authentic human ex vivo models of the bronchial epithelium from normal and asthmatic
children. We assessed the effects of IL-9, IL-13 and an IL-9/IL-13 combination, during differentiation of bronchial epithelial
cells from normal (n = 6) and asthmatic (n = 8) children. Cultures were analysed for morphological markers and factors
associated with altered differentiation (MUC5AC, SPDEF and MMP-7). IL-9, IL-9/IL-13 combination and IL-13 stimulated
bronchial epithelial cells from normal children had fewer ciliated cells [14.8% (SD 8.9), p = 0.048, 12.4 (SD 6.1), p = 0.016 and
7.3% (SD 6.6), p = 0.031] respectively compared with unstimulated [(21.4% (SD 9.6)]. IL-9 stimulation had no effect on goblet
cell number in either group whereas IL-9/IL-13 combination and IL-13 significantly increased goblet cell number [24.8% (SD
8.8), p = 0.02), 32.9% (SD 8.6), p = 0.007] compared with unstimulated normal bronchial cells [(18.6% (SD 6.2)]. All
stimulations increased MUC5AC mRNA in bronchial epithelial cells from normal children and increased MUC5AC mucin
secretion. MMP-7 localisation was dysregulated in normal bronchial epithelium stimulated with Th2 cytokines which
resembled the unstimulated bronchial epithelium of asthmatic children. All stimulations resulted in a significant reduction
in transepithelial electrical resistance values over time suggesting a role in altered tight junction formation. We conclude
that IL-9 does not increase goblet cell numbers in bronchial epithelial cell cultures from normal or asthmatic children. IL-9
and IL-13 alone and in combination, reduce ciliated cell numbers and transepithelial electrical resistance during
differentiation of normal epithelium, which clinically could inhibit mucociliary clearance and drive an altered repair
mechanism. This suggests an alternative role for IL-9 in airways remodelling and reaffirms IL-9 as a potential therapeutic
target.
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Introduction
Asthma is a chronic inflammatory disease of the lower airways
which tends to begin during childhood [1,2]. One in seven
children in the UK are affected by asthma and as a result represent
a major financial burden on the NHS which is worsened when
asthma is poorly controlled [3]. Additionally, asthma is one of the
most common chronic diseases worldwide with approximately 300
million individuals affected [4]. Traditional treatments, including
inhaled corticosteroids and short and long-acting b2-agonists, are
used to control asthma symptoms and exacerbations, however in a
small group of severe asthmatics their efficacy is poor. Addition-
ally, current treatments do not address the underlying issue of
airways remodelling.
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Airways remodelling in asthma is characterised by non-
reversible changes in the bronchial epithelium including goblet
cell hyperplasia, mucus hyper-secretion, sub-epithelial fibrosis,
smooth muscle hypertrophy and increased basement membrane
thickening [5]. This in turn leads to airflow obstruction which can
be life-threatening with approximately 1500 deaths per year in the
UK as a result of asthma [6,7]. The dramatic change in the
phenotype of the airway is caused by a shift from a balanced Th1/
Th2 phenotype to a chronic Th2 pro-inflammatory phenotype
causing dysregulation and/or aberrant repair of the bronchial
epithelium [8–10]. It has been reported that asthmatic airways
have abnormal barrier function which in turn leads to chronic
tissue injury and altered repair mechanisms [10,11]. Several
inflammatory mediators have been implicated in in the develop-
ment of airways remodelling including the Th2 cell cytokines IL-9
and IL-13. Cytokines have become viable therapeutic targets
because of the lack of effect of traditional therapies in severe
asthma.
IL-9 is a pleiotropic Th2 cytokine released by a subset of CD4+
cells designated Th9 cells [12,13] and has been identified as a
candidate cytokine for asthma pathogenesis [14]. In murine
models IL-9 stimulates mucin transcription and goblet cell
hyperplasia [15] and by over-expressing IL-9 in the lungs of a
transgenic mouse model it also induced IL-13 production from
airway epithelial cells [16]. It is still unclear whether the role of IL-
9 is that of a dominant cytokine or one of a helper cytokine in
asthma. A recent study using cultures of micro-dissected murine
terminal bronchioles has found that a combination of IL-9 and IL-
13 increased goblet cell hyperplasia [17]. Xiang and colleagues
suggested that IL-9 and IL-13 may act independently on airway
epithelial cells to regulate mucin synthesis and in addition show an
overall synergistic effect [17]. As a result of this and other studies,
IL-9 and IL-13 have been identified as potential therapeutic
targets. In particular, inhibition of IL-9 has shown promising
results in reducing allergic inflammation and mucus hypersecre-
tion in mice and in clinical studies an IL-9 blocking antibody has
been shown to reduce exercise-induced asthma [18].
In the only study to date to have examined differentiated human
airway epithelial cells, Vermeer et al. found that IL-9 induced
goblet cell hyperplasia both during differentiation and in a
mechanical injury model using cells obtained from the trachea
[19]; this effect was not seen in cells exposed to IL-9 post-
differentiation which suggested that this effect only occured during
the differentiation process. The role of IL-9 in bronchial epithelial
cell differentiation, how it affects cells from asthmatic subjects and
how it acts in combination with IL-13 in paediatric bronchial
epithelial cell differentiation remains unclear. With the potential of
IL-9 being a clinical therapeutic target, it is important to
understand its actions on the bronchial epithelium, in both health
and disease. The ex vivo well-differentiated model of bronchial
epithelial cells has been shown to closely resemble the in vivo
epithelium making it the ideal model for further study of the effects
of the Th2 cytokines on airways remodelling [20].
In this paper we will assess morphological markers of airways
remodelling as an output of altered differentiation in response to
direct stimulation of the bronchial epithelial cells with IL-9 and IL-
13 alone and combined. These will include quantification of goblet
and ciliated cell number, MUC5AC, the major mucus forming
mucin, SAM-pointed-domain-containing-Ets-like factor (SPDEF),
a transcription factor known to be involved in the goblet cell
hyperplasia pathway [21] and matrix metalloproteinase (MMP) -7
which has been shown to have dysregulated expression in the
asthmatic epithelium due to Th2 cytokine exposure [22].
We hypothesise that IL-9 alone and in combination with IL-13
in a synergistic fashion will contribute to goblet cell hyperplasia
and a reduction in ciliated cells in paediatric bronchial epithelial
cell differentiation. We used a well-differentiated model of
bronchial epithelial cells from normal (PBEC(N)) and asthmatic
(PBEC(A)) children.
Materials and Methods
Ethics statement
Written informed parental consent and where appropriate child
assent was obtained. This study was approved by the Office of
Research Ethics Committees Northern Ireland (ORECNI, Refer-
ence Number: 07/NIR02/141).
Subjects
Children less than 12 years (mean age 7.3 years [range: 1 to 12
years]) attending elective surgical procedures at the Royal Belfast
Hospital for Sick Children were recruited. A doctor administered
questionnaire was used to record the clinical history. Recruited
children included asthmatics (recurrent wheezing within the last
year – mean age 6.3 years, n = 8) or normal controls (mean age 8.5
years, n = 6) who had never wheezed. Seven of the asthmatic
children had other atopic features (allergic rhinitis and/or eczema,
or an elevated total IgE). All asthmatic children were being treated
with inhaled corticosteroids (ICS) and four were also on long-
acting beta 2 agonists (two of these additionally were on
leukotriene antagonists). The healthy controls had no respiratory
symptoms and were on no asthma therapy. One healthy control
child had eczema and this and one other child had an isolated
elevated total IgE.
Isolation of primary PBECs
Non-bronchoscopic bronchial brushings were used to sample
and culture bronchial epithelial cells from asthmatic children
(n= 8) and normal children (n = 6) as previously described [23,24].
A number of these samples were also used in our previous study
for IL-13 exposure [25]. This represents a culture success rate of
70% of PBEC samples received. All brush washings were analysed
for viruses using a multi-viral PCR analysis and only uncontam-
inated cultures were used [26].
ALI cultures for establishment of well-differentiated
mucociliary epithelium
Air liquid interface (ALI) cultures were grown in line with
methods previously described [23,24,25,27,28]. Briefly, all cells
from subjects used in this study were grown at ALI at passage 2 in
ALI medium consisting of a 50:50 mixture of AEGM (Promocell,
Heidelberg, Germany) and DMEM (Invitrogen Ltd, Paisley, UK)
supplemented with bovine pituitary extract (52 mg/ml), epidermal
growth factor (0.5 ng/ml), insulin (5 mg/ml), hydrocortisone
(0.5 mg/ml), epinephrine (0.5 mg/ml), transferrin (10 mg/ml),
bovine serum albumin (1.5 mg/ml), penicillin/streptomycin
(100 IU/ml/100 mg/ml) and retinoic acid (50 nM). The cells
were grown in transwells submerged for the first 9 to 14 days,
during which time the culture medium was changed on day 1 and
every other day thereafter. Once the cells reached 100%
confluence, ALI was created by removing the apical medium
and restricting the culture feeding to the basolateral compartment.
Following ALI creation, the culture medium was changed on
alternate days and the cells were then differentiated over 28 days
to ensure full differentiation as assessed by the presence of beating
cilia and mucus on the apical surface of the cultures. Primary
paediatric bronchial epithelial cells (PBECs) were fed every other
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day with ALI medium alone as an unstimulated control, or
supplemented with 20 ng/ml IL-9, 20 ng/ml IL-13 or 20 ng/ml
IL-9/IL-13 combination during the differentiation process (Pe-
ProTech EC, Scotland, UK). These concentrations were selected
following intial dose-response studies (data not shown) in the case
of IL-13. All WD-PBECs included reached full differentiation at
ALI.
Transepithelial Electrical Resistance (TEER) measurements
TEER was measured on days 7, 14, 21, and 28 to ensure the
formation and integrity of tight junctions between cells in the
epithelium using an EVOM meter (World Precision Instruments,
FL, USA).
ELISA measuring IL-9 and IL-13
Cytokine concentrations were measured from aliquots of
basolateral culture medium and apical washings taken on days
7, 14, 21 and 28 of culture using commercial ELISA kits (IL-9:
PeProTech EC, Scotland, UK; IL-13: Pierce BioScience, North-
umberland, UK) as per manufacturers instructions.
Immunocytochemistry (ICC) for goblet and ciliated cell
markers
ICC was carried out using methods previously described
[24,25]. Briefly, immuno-staining was performed using mouse
anti-MUC5AC antibody (1:100) (Abcam, UK) and mouse anti-
acetylated alpha tubulin antibody (1:700) (Abcam, UK) for goblet
and ciliated cells respectively. The reaction between the antigen
and the antibody was detected using a perixodase-conjugated anti-
mouse secondary antibody (Vector Laboratories, Peterborough,
UK). The slides were then stained with DAB substrate kit (Vector
Laboratories, Peterborough, UK) for visualization. Negative
controls were subjected to routine conditions with the omission
of the primary antibody. MUC5AC (goblet cells) and acetylated
alpha tubulin (ciliated cells) positive cells were counted at a
magnification of640 blindly in 6 fields of vision. A total number
of 500 cells per slide were enumerated and the number of positive
cells for MUC5AC or acetylated alpha tubulin was then expressed
as a percentage of the total cells counted per slide. Three slides per
stain (MUC5AC or acetylated alpha tubulin) per insert were
enumerated and in this paper the results represent the mean
percentage of those three slides. As there were no significant
differences between the total numbers of cells at the end of the
culture period the percentages presented are representative of the
total proportions of goblet and ciliated cells within the epithelium.
Immunofluorescence (IF) and confocal microscopy
IF and confocal microscopy were carried out using methods
previously described [24,25]. Briefly, a 1:100 dilution of mouse
monoclonal antibody against acetylated alpha tubulin (ciliated
cells) (Abcam, Cambridge, UK), a 1:100 dilution of mouse
monoclonal antibody against cytokeratin 5/8 conjugated to
AF488 (Insight Biotechnology, UK) or a 1:100 dilution of rabbit
polyclonal antibody against MMP-7 (Abcam, UK) was incubated
with selected inserts overnight at 4uC. Cells were exposed to a
1:250 dilution of goat anti-rabbit IgG Alexafluor 568 (MMP-7)
(Invitrogen Ltd, Paisley, UK) or a 1:250 dilution of Alexafluor 488
goat anti-rabbit IgG (ciliated cells) (Invitrogen Ltd, Paisley, UK) at
4uC in the dark for 1 hour. The membrane was cut out from the
insert using a scalpel and then mounted on a slide using
Vectashield with DAPI (Vector Laboratories, Peterborough,
UK). Fluorescent images were viewed on a Leica SP5 confocal
DMI 6000 inverted microscope equipped with a krypton-argon
laser as the source for the ion beam using 640 oil immersion
(numerical aperture 1.25). Images were captured and viewed using
LAS AF (Leica) acquisition software. Negative controls (omission
of primary antibody) were used to test the specificity of the
antibodies and the staining protocol.
Z-series stacks of representative cultures acquired using the
Leica SP5 confocal microscope were analysed step-wise for total
staining area of MMP-7 using FIJI software (Image J) to detect
semi-quantitatively the localisation (apical, middle or basal) of
MMP-7 throughout the PBEC(N) & (A) cultures.
RNA extraction and Real-time PCR
RNA extraction was carried out using RNeasy Mini kit (Qiagen,
Crawley, UK) according to the manufacturer’s instructions and
quantified on a spectrophotometer. First Strand cDNA Synthesis
Kit for RT-PCR (AMV) (Roche, UK) was then used according to
the manufacturer’s protocol. For the real time PCR reaction, the
DNA amplification was carried out using the Fast Start Universal
SYBR Green Master (Rox) (Roche, UK) according to the
manufacturers’ protocol. For each PCR reaction separate PCR
Master Mixes were prepared containing GAPDH (Tebu-bio,
Peterborough, UK), IL-13 (R&D Systems, Abingdon, UK),
MUC5AC (Invitrogen, Paisley, UK), MMP-7 (Invitrogen, Paisley,
UK) and SPDEF (Invitrogen, Paisley, UK) primers. MUC5AC,
MMP-7 and SPDEF primer sequences are listed in the supple-
mentary section (Primer Sequence S1). A final total volume of
10 ml was constituted with the addition of 1 ml of cDNA added
into each Master Mix. Samples were placed in individual wells in a
Thermo-Fast 96-well detection plate and run on the spectroflu-
orometric thermal cycler AB 7000 (ABI Prism).
ELISA measuring MUC5AC mucin
MUC5AC mucin was measured from apical washings taken
from the cultures on day 28 using ELISA. The method used was
adapted from Takeyama and co-workers [29]. Results were
expressed as optical density proportional to MUC5AC secretion,
which is directly proportional to the amount of mucin present,
with a positive mucin control used across experiments.
Statistical analysis
Our a priori aims in this study were to make planned
comparisons between the effects of IL9, alone and combined with
IL13 versus no stimulation (control) on differentiation and to
compare IL9 with IL13 stimulation. We first compared stimula-
tion responses using one way repeated measures ANOVA (RM-
ANOVA) and if the overall RM-ANOVA was statistically
significant (p#0.05) we then performed planned unadjusted
paired t-tests expressing results as mean (standard deviation,
SD). For comparisons of TEER measurements we analysed data
using a two-way repeated measures ANOVA (TEER over Time
by Normal versus Asthmatic).
Results
All cultures exhibited a well-differentiated pseudostratified
epithelium with ciliated cells and goblet cells as well as TEER
values above 300 ohm.cm2, which supported the visual appear-
ance of a morphologically intact epithelium with tight junction
formation. No IL-13 mRNA was detected in unstimulated cells or
cells exposed to IL-9 and IL-9/IL-13 combination using real time
PCR (data not shown). Neither IL-9 or IL-13 were detected in
basolateral supernatants or apical washings using ELISAs (data
not shown). The total cell counts at the end of the culture period
showed there to be no significant difference between unstimulated
IL-9 Effects on a Bronchial Epithelial Cell Model
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and IL-9, IL-13 or IL-9/IL-13 combination stimulated cultures in
both groups (data not shown). It is worth noting that it is extremely
unlikely given the number of passages the cells go through (cells
are differentiated at passage 2) along with the length of time from
sampling to completion of culture (7–10 weeks) that there would
be any carry-over effect of inhaled corticosteriods.
PBEC(N) stimulation with IL-9, IL-13 or IL-9/IL-13
combination
Regarding ciliated cells we found that all cytokine stimulations
caused a significant reduction in the percentage of ciliated cells
[IL-9 stimulated: mean 14.8% (SD 8.9), p = 0.048); IL-9/IL-13
combination: mean 12.4% (SD 6.1), p = 0.016; IL-13 stimulated:
mean 7.3% (SD 6.6), p = 0.031)], versus unstimulated [unstimu-
lated: mean 21.4% (SD 9.6)] (Figure 1A). No difference was seen
in the percentage of goblet cells in PBEC(N) after stimulation with
IL-9 alone [unstimulated: mean 18.6% (SD 6.2); IL-9 stimulated:
mean 20.2% (SD 6.3)] (Figure 1B). IL-9/IL-13 combination and
IL-13 alone significantly increased the percentage of goblet cells
compared with unstimulated control [IL-9/IL-13 combination:
mean 24.8% (SD 8.8), p = 0.02; IL-13 stimulated: mean 32.9%
(SD 8.6), p = 0.007; versus unstimulated: mean 18.6% (SD 6.2)
(Figure 1B)].
IL-9 stimulation did not increase SPDEF mRNA compared
with control [IL-9 stimulation: mean 1.038 (SD 0.49)] whereas IL-
9/IL-13 combination and IL-13 did but the increase was not
statistically significant [IL-9/IL-13 combination: mean 2.02 (SD
0.72); IL-13: mean 2.77 (SD 1.6)] (Figure 2A).
MUC5AC mRNA increased (fold change) significantly in
PBEC(N) for all cytokine stimulations [IL-9 stimulated: mean
3.1 (SD 1.7), p = 0.02; IL-9/IL-13 combination: mean 2.3 (SD
0.8), p = 0.02; IL-13 stimulation: mean 4.3 (SD 3.0), p = 0.04]
(Figure 3A).
A trend for increased secreted MUC5AC mucin at the apical
surface was observed using ELISA between unstimulated [un-
stimulated: mean 2.02 (SD 0.7)] and all cytokine stimulations [IL-9
stimulated: mean 2.72 (SD 0.6); IL-9/IL-13 combination: mean
2.6 (SD 0.7); IL-13 stimulated: mean 2.84 (SD 0.4)] (Figure 4A).
MMP-7 mRNA increased (fold change) in PBEC(N) for IL-9/
IL-13 combination stimulation [IL-9/IL-13 combination: mean
6.3 (SD 7.7), p = 0.050] but not significantly. IL-9 and IL-13
stimulation [IL-9 stimulated: mean 3.4 (SD 3.6), p = 0.06; IL-13
stimulation: mean 9.0 (SD 13.7)] showed a similar trend to that of
the IL-9/IL-13 combination (Figure 5A).
In terms of MMP-7 localisation within the epithelial cells we
found that in unstimulated epithelium, MMP-7 expression (red)
was localised mainly to the apical surface along with the ciliated
cells (green) (Figure 6A) and separate from the basal cells (green) of
the epithelium (Figure 6B & 7A). When stimulated with IL-9 we
found dysregulation of MMP-7 (red) at the apical surface
(Figure 6C) while being more dispersed throughout the middle
and basal epithelial layers (green) (Figure 6D & 7B). When
stimulated with IL-9/IL-13 combination we noticed a similar
localisation of MMP-7 (red) expression as with the control cultures
at the apical surface, albeit with fewer ciliated cells (green)
(Figure 6E) and stronger basal cell (green) staining (Figure 6F &7C)
with lower expression of MMP-7 (red) expressed throughout. IL-
13 stimulation not only decreased ciliated cell number (green) and
reduced apical MMP-7 (red) expression (Figure 6G) but was also
associated with increased MMP-7 expression (red) throughout the
basal epithelial cell layers (green) (Figure 6H & 7D). Negative
controls were also analysed for non-specific staining (Figure 6K).
PBEC(A) stimulation with IL-9, IL-13 or IL-9/IL-13
combination
In relation to ciliated cell numbers, we found that only IL-13
stimulation alone contributed to a significant reduction in the
percentage of ciliated cells [IL-13 stimulation: mean 5.8% (SD
1.6)] compared with unstimulated [unstimulated: mean 15.5%
(SD 2.3), p = 0.0004)] (Figure 1C). This reduction in the
percentage of ciliated cell numbers was not seen in asthmatic
cells with IL-9 stimulation alone or in combination with IL-13
(Figure 1C). The percentage of goblet cells in PBEC(A) increased
following stimulation with IL-13 [IL-13 stimulation: mean 45.2%
(SD 17.2)] compared with unstimulated [unstimulated: mean
35.8% (SD 21.4)] (Figure 1D), however this was not statistically
significant. No differences were seen with IL-9 stimulation alone or
in combination with IL-13 (Figure 1D).
SPDEF mRNA showed a significant increase under IL-9/IL-13
and IL-13 stimulation compared with control [IL-9/IL-13
combination: mean 2.3 (SD 1.2), p = 0.005; IL-13 stimulation:
mean 2.84 (SD 1.5), p = 0.028] (Figure 2B). Additionally SPDEF
mRNA also showed significant differences between IL-9 and IL-9/
13 combination [IL-9 stimulation: mean 1.02 (SD 0.4); IL-9/IL-13
combination: mean 2.3 (SD 1.2), p = 0.002] and IL-13 [IL-9
stimulation: mean 1.02 (SD 0.4); IL-13 stimulation: mean 2.84 (SD
1.5), p = 0.03] (Figure 2B).
MUC5AC mRNA from PBEC(A) showed a significant fold
change only in IL-13 stimulated PBEC(A) compared with
unstimulated control [IL-13 stimulation: mean 2.43 (SD 1.2),
p = 0.016] (Figure 3B). Additionally IL-13 showed a significant
increase in MUC5AC mRNA compared with IL-9 alone [IL-9
stimulation: mean 0.79 (SD 0.6), p = 0.01] and IL-9/IL-13
combination [IL-9/IL-13 combination: mean 0.82 (SD 0.7),
p = 0.01] (Figure 3B). In PBEC(A) no difference was observed in
secreted MUC5AC following any of the cytokine stimulations [IL-
9 stimulated: mean 2.6 (SD 0.6); IL-9/IL-13 combination: mean
2.8 (SD 1.1); IL-13 stimulated: mean 2.6 (SD 0.9)] when compared
with unstimulated control [unstimulated: mean 2.6 (SD 0.5)]
(Fig. 4B).
MMP-7 mRNA showed no significant increase (fold change) in
PBEC(A) for any of the stimulations [IL-9 stimulated: mean 1.7
(SD 1.4); IL-9/IL-13 combination: mean 2.2 (SD 2.0); IL-13
stimulation: mean 2.6 (SD 3.2)] however all stimulations showed a
trend for increase (Figure 5B).
In terms of MMP-7 staining, the asthmatic epithelium showed
dysregulated expression of MMP-7 (red) along with fewer ciliated
cells (green) at the apical surface (Figure 6I) and a large proportion
of basal undifferentiated epithelial cells (green) with greater MMP-
7 (red) expression present throughout the middle and lower
epithelial cell layers (Figure 6J & 7E).
Comparison of TEER values between PBEC(N) and
PBEC(A) stimulated with IL-9, IL-9/IL-13 combination and
IL-13
TEER values compared over time by clinical description
(Normal or Asthmatic) using a 2-way repeated measures ANOVA
demonstrated no significant difference between PBEC(N) and
PBEC(A) in any of the outcomes measured under unstimulated
conditions (time p= 0.3; clinical p = 0.07; interaction (ie. does
PBEC(A) behave differently from (PBEC(N) over time) p= 0.07)
(Figure 8A). Under stimulation with IL-9 there were significant
differences over time and for clinical (time p= 0.04; clinical
p = 0.03) however there was no significant interaction (interaction
p= 0.09) (ie/. PBEC(N) and PBEC(A) respond in a similar way to
stimulation with IL-9) (Figure 8B). Similar results were observed
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with IL-9/IL-13 stimulation (time p= 0.02; clinical p = 0.005;
interaction p= 0.7) (Figure 8C) and with IL-13 (time p= 0.01;
clinical p = 0.0004; interaction p= 0.4) (Figure 8D).
Discussion
Our main findings from this study were (1) that IL-9, IL-9/IL-
13 combination and IL-13 stimulation, in PBEC(N), and IL-13 in
PBEC(A), resulted in a significant reduction in the ciliated cell
number; (2) that IL-9 stimulation alone did not induce goblet cell
hyperplasia in either PBEC(N) or PBEC(A); (3) IL-9 showed no
synergy with IL-13 stimulation with respect to goblet cell
hyperplasia; (4) IL-9, IL-9/IL-13 combination and IL-13 stimu-
lation in PBEC(N) and PBEC(A) significantly reduced TEER over
the duration of the differentiation process.
Although IL-9 has been implicated in goblet cell hyperplasia
[19] we have found that it had no significant effect on goblet cell
number in differentiating PBEC(N) and PBEC(A). This data
Figure 1. Percentage of goblet and ciliated cells in PBEC(N) and (A) cultures. (A) Numbers of ciliated cells expressed as a percentage of total
on day 28 for PBEC(N) stimulated with IL-9, IL-9/IL-13 combination and IL-13. Values are expressed as mean (error bar represents 1 SD). A repeated
measures ANOVA overall p value of p= 0.05 was obtained. The percentage of ciliated cells decreased with IL-9 (p = 0.048), IL-9/IL-13 combination
(p = 0.016) and IL-13 (p = 0.031) stimulations. (B) Numbers of goblet cells expressed as a percentage of total on day 28 for PBEC(N) stimulated with IL-
9, IL-9/IL-13 combination and IL-13. Values are expressed as mean (error bar represents 1 SD). A repeated measures ANOVA overall p value of
p = 0.000007 was obtained. The percentage of goblet cells increased with IL-9/IL-13 combination stimulation (p = 0.02) and IL-13 stimulation
(p = 0.007). (C) Numbers of ciliated cells expressed as a percentage of total on day 28 for PBEC(A) stimulated with IL-9, IL-9/IL-13 combination and IL-
13. Values are expressed as mean (error bar represents 1 SD). A repeated measures ANOVA overall p value of p = 0.011 was obtained. The percentage
of ciliated cells decreased with IL-13 stimulation (p = 0.0004). (D) Numbers of goblet cells expressed as a percentage of total on day 28 for PBEC(A)
stimulated with IL-9, IL-9/IL-13 combination and IL-13. Values are expressed as mean (error bar represents 1 SD). A repeated measures ANOVA overall
p value of p = 0.15 was obtained. There was no statistically significant increase in the percentage of goblet cells under any cytokine stimulation.
doi:10.1371/journal.pone.0061023.g001
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differs, in part, with that of Vermeer and colleagues who
demonstrated that IL-9 induced goblet cell hyperplasia during
differentiation or in the already differentiated epithelium following
an epithelial insult [19]. There were a few notable differences
between the two studies. Vermeer studied adult tracheal airway
cells whereas we used paediatric bronchial epithelial cells.
Additionally, Vermeer and colleagues used a higher concentration
of IL-9 and IL-13 for their experiments. We have previously
shown that 20 ng/ml IL-13 alone induces a significant increase in
goblet cell numbers [25] and this is an observation we have again
confirmed in this study, thereby demonstrating consistency in both
our model and the culture conditions. This may go some way to
explaining some of the differences observed. In combination with
IL-9, the IL-13 effect on goblet cell numbers is observed; however
we found no evidence for synergy between IL-9 and IL-13, as
suggested by Xiang and colleagues [17]. Instead, our data suggests
that IL-13 is acting alone and, if anything, when combined with
IL-9, this tended to reduce the effect of IL-13. This may suggest an
inhibitory effect of IL-9 on the function of IL-13 which certainly
warrants future investigation.
We observed an up-regulation of MUC5AC mRNA in
PBEC(N), with a subsequent trend to increased MUC5AC
secretion in apical supernatants, suggesting that with further
investigation, IL-9 may have a role to play in mucin production.
While goblet cell hyperplasia and increased mucus secretion are
characteristics of the asthmatic epithelium they are separate
Figure 2. Fold change of SPDEF mRNA measured using real time PCR. (A) In PBEC(N) on day 28 of ALI culture we observed an increase in
SPDEF mRNA by stimulation with IL-9/IL13 combination and IL-13 however this was not statistically significant. A repeated measures ANOVA overall p
value of p = 0.11 was obtained. (B) In PBEC(A) a repeated measures ANOVA overall p value of p = 0.0004 was obtained. A significant difference was
observed only with IL-9/IL-13 combination (p = 0.005) and IL-13 stimulation (p = 0.028) compared with unstimulated. Additionally significant increases
were also observed between IL-9 and IL-9/IL-13 combination (p = 0.002) and between IL-9 and IL-13 (p = 0.03).
doi:10.1371/journal.pone.0061023.g002
Figure 3. Fold change of MUC5AC mRNA measured using real time PCR. (A) In PBEC(N) on day 28 of ALI culture we observed a repeated
measures ANOVA overall p value of p = 0.05. A significant increase in MUC5AC mRNA by stimulation with IL-9 (p = 0.02), IL-9/IL13 combination
(p = 0.02) and IL-13 (p = 0.04) was observed. (B) In PBEC(A) a repeated measures ANOVA overall p value of p= 0.00098 was obtained. A significant
increase compared with unstimulated was observed only with IL-13 stimulation (p = 0.016). Additionally, there were significant differences in
MUC5AC mRNA between IL-9 and IL-13 stimulations (p = 0.01) and between IL-9/IL-13 combination and IL-13 stimulations (p = 0.01).
doi:10.1371/journal.pone.0061023.g003
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morbidities. This role for IL-9 would fit with the observation of
reduced mucus hypersecretion in a murine model treated with IL-
9 inhibitors [18]. Additionally IL-9 did not increase SPDEF
mRNA, a key transcription factor implicated in the goblet cell
hyperplasia pathway [21] whereas the IL-9/IL-13 combination
and IL-13 alone showed a trend for increase in PBEC(N) and
significantly increased SPDEF levels in asthmatic epithelium.
Taking this data into account we feel that the lack of effect of IL-9
on goblet cell hyperplasia is real due to IL-9 demonstrating other
alternative functions within our culture system.
We observed a significant reduction in the numbers of ciliated
cells in PBEC(N) stimulated with IL-9, an observation which was
also noted by Vermeer and colleagues [19]. Vermeer suggested the
reduction in ciliated cell numbers was due to replacement with
goblet cells; however our data showed that this was not the case,
and that the reduction in ciliated cells is independent of goblet cell
numbers. In addition, we identified no difference in total cell
numbers in IL-9 stimulated cells (data not shown), consistent with
inhibition of differentiation to ciliated cells, and our previous data
demonstrates in this setting, greater numbers of basal, undiffer-
entiated cells [24]. A recent study by Wadsworth et al. showed that
in well differentiated epithelium from non-asthmatic subjects,
ciliated cells expressed strong levels of matrix metalloproteinase-7
(MMP-7), which is important in the innate immunity of the
airway. MMP-7 is not normally highly expressed in undifferen-
tiated basal cells, except during wound repair [22]. In poorly
differentiated epithelial cells from asthmatic patients they found
MMP-7 expression to be present in basal cells, suggesting an
injured and dysregulated epithelium [22]. When they stimulated
normal epithelial cell lines with a Th2 cytokine mix, including IL-9
and IL-13, they observed an increased endogenous MMP-7
activity and concluded that high levels of Th2 cytokines could
result in a prolonged increase in MMP-7 activity, leading to
airways remodelling [22]. This would support our findings of an
Figure 4. Average relative optical density of apical washings measured for MUC5AC secretion. Values expressed are mean (error bar
represents 1 SD). (A) In PBEC(N) on day 28 of ALI culture we observed higher amounts of MUC5AC at all cytokine stimulations, however this was not
statistically significant. A repeated measures ANOVA overall p value of p = 0.068 was obtained. (B) In PBEC(A) we observed no significant difference in
the amount of MUC5AC secreted in any of the cytokine stimulation groups. A repeated measures ANOVA overall p value of p = 0.8 was obtained.
doi:10.1371/journal.pone.0061023.g004
Figure 5. Fold change of MMP-7 mRNA measured using real time PCR. (A) In PBEC(N) on day 28 of ALI culture we observed a repeated
measures ANOVA overall p value of p= 0.04. IL-9/IL13 combination (p = 0.05) and IL-9 stimulation showed an increase in MMP-7 mRNA (p= 0.06) as
did IL-13 however these were not significant. (B) In PBEC(A) a there was no significant increase with any stimulation. A repeated measures ANOVA
overall p value of p= 0.81 was obtained.
doi:10.1371/journal.pone.0061023.g005
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inhibition of differentiation to ciliated cells in PBEC(N) exposed to
Th2 cytokines. Using immunofluorescence coupled with confocal
microscopy we found that unstimulated PBEC(N) expressed
MMP-7 at the apical surface of the epithelium, largely associated
with ciliated cells, with almost no expression in the basal cells of
the epithelium, as had been shown by Wadsworth et al. [22].
Additionally, we also showed that in PBEC(A) MMP-7 expression
is less localised to the the apical surface likely due to there being
fewer ciliated cells inherently in PBEC(A) [24], with higher
expression also being observed throughout the basal layers of the
epithelium, confirming suggestions that the asthmatic epithelium is
morphologically dysregulated compared with PBEC(N) [22,24].
We found that IL-9, IL-9/IL-13 combination and IL-13 altered
the differentiation process of PBEC(N) to varying degrees, where
we observed pronounced effects on the reduction of ciliated cells,
the increased expression of basal epithelial cells and dysregulated
localisation of MMP-7 throughout the epithelium when compared
with unstimulated PBEC(N). PBEC(N) stimulated with IL-13 in
particular also represented visually the unstimulated PBEC(A)
epithelium. We found that MMP-7 mRNA was increased in all
stimulations but not significantly, suggesting that Th2 cytokines
can increase MMP-7 transcription, while also contributing to
dysregulation of MMP-7 localisation in the airway combined with
a reduction in ciliated cells, an observation also noted by
Wadsworth et al. [22].
Additional effects of Th2 cytokine stimulation were observed in
relation to tight junction formation. All stimulations (IL-9, IL-9/
IL-13 combination and IL-13) significantly reduced the TEER
values over the time course of the cultures and also highlighted
significant differences between PBEC(N) and PBEC(A). However,
under unstimulated conditions there were no significant differ-
ences between PBEC(N) and PBEC(A) suggesting that it is only
during chronic Th2 cytokine exposure that epithelial differences
between the two phenotypes become apparent. This observation
has been demonstrated by our previous studies [24,25] however
another group have found significant differences between un-
stimulated PBEC(N) and PBEC(A) [10]. This difference may be
explained by the severity of the asthmatic patients sampled. Xiao et
al. described significant differences in TEER values between a
group of severe asthmatics compared with control whereas we
sampled mild asthmatic subjects for this study. Additionally, it
would be interesting to see if the TEER values returned to baseline
following removal of the Th2 stimulus, however that was not part
of this study.
The reduction in ciliated cells and the effect the cytokines had
on epithelial integrity may represent important effects in vivo, with
resultant reduction in the tightness of the epithelium and the
capacity to clear excess mucus from asthmatic airways. Recent
data supports profound ciliary dysfunction associated with
epithelial damage in subjects with severe asthma [30] whilst other
groups have also highlighted differences in epithelial barrier
function, albeit under unstimulated as well as stimulated condi-
tions [10]. Thus, an important contribution of IL-9, in asthma,
may instead be on epithelial integrity and ciliated cell number and
function, leading to impaired mucus clearance, particularly in
severe disease, something that can be said of IL-13 as well. This
would point towards Th2 cytokines still being a therapeutic target
with a focus on the effects of IL-9 on epithelial integrity, ciliated
cell differentiation and mucus hypersecretion [18].
There were a number of limitations within this study. Firstly,
due to the small initial cell sample we obtained from the airways of
subjects we are limited in the number of experimental conditions
and subsequent analyses, even following expansion in tissue
culture flasks. This resulted in only being able to stimulate the cells
with one concentration of IL-9. Ideally it would have been
interesting to stimulate cells with a suboptimal dose of IL-13 when
combined with IL-9 in addition to the dose tested to identify
whether any inhibitory effects of IL-9 on IL-13 function were
present. Secondly, while it would have been ideal to measure the
transcription factor SPDEF in an acute fashion (ie/. hours
following Th2 cytokine exposure) due to the nature of the
hyopthesis and the limited number of cells, we had to analyse at
the final time point, in line with all other analyses.
Figure 6. Immunofluorescent staining coupled with confocal
microscopy for assessment of localisation of MMP-7 in
representative PBEC(N) and (A). Representative z-stack orthogonal
cut images of MMP-7 (red) and ciliated cell (green) expression of
PBEC(N) at day 28 ALI culture for unstimulated (A), IL-9 stimulated (C),
IL-9/IL-13 combination stimulated (E), IL-13 stimulated (G) and
representative z-stack orthogonal cut images of MMP-7 (red) and basal
epithelial cells (green) expression of PBEC(N) at day 28 ALI culture for
unstimulated (B), IL-9 stimulated (D), IL-9/IL-13 combination stimulated
(F), IL-13 stimulated (H). PBEC(A) representative images of MMP-7 (red)
and ciliated cells (green) for unstimulated (I) and MMP-7 (red) and basal
epithelial cells (green) for unstimulated (J). Negative control (K). The
nuclei in each image are stained with DAPI (blue).
doi:10.1371/journal.pone.0061023.g006
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In conclusion, we have found that IL-9 can elicit detrimental
effects on epithelial tight junctions, ciliated cell differentiation and
mucus hypersecretion, rather than on goblet cell hyperplasia, as
was previously thought [15,17,19] which may be physiologically
important in vivo, reinforcing IL-9 as a potential therapeutic target
in asthma
Figure 7. Semi-quantification of Total Area Staining for MMP-7 localisation throughout Z-series stacks of representative PBEC(N)
and (A). (A) Unstimulated PBEC(N) on Day 28 of culture demonstrates high levels of staining for MMP-7 localisation in the Apical layer with minimal
staining in the middle and basal layers. (B) IL-9 stimulated PBEC(N) on Day 28 of culture demonstrates a more even spread of MMP-7 staining
throughout all levels of the culture. (C) IL-9/IL-13 combination stimulated PBEC(N) on Day 28 of culture demonstrates a higher expression pattern of
MMP-7 in the Apical layers with lower staining in the middle and basal layers of the culture. (D) IL-13 stimulated PBEC(N) on Day 28 of culture
demonstrates a low apical and middle expression of MMP-7 and a higher basal expression in the culture. (E) Unstimulated PBEC(A) on Day 28 of
culture demonstrates a progressive increase in MMP-7 expression from the apical to the basal layers of the culture.
doi:10.1371/journal.pone.0061023.g007
IL-9 Effects on a Bronchial Epithelial Cell Model
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e61023
Supporting Information
Primer Sequence S1 Primer Sequence S1
(DOC)
Author Contributions
Conceived and designed the experiments: JCP ST GS LGH MDS.
Performed the experiments: JCP ST JB. Analyzed the data: JCP ST MDS.
Contributed reagents/materials/analysis tools: JCP ST JB MDS. Wrote
the paper: JCP ST MDS LGH. Anaesthetist: JL.
References
1. Cutz E, Levison H, Cooper DM (2002) Ultrastructure of airways in children
with asthma. Histopathology 41:22–36.
2. Pohunek P, Warner JO, Turzikova J, Kudrmann J, Roche WR (2005) Markers
of eosinophilic inflammation and tissue remodelling in children before clinically
diagnosed bronchial asthma. Pediatr Allergy Immunol 16(1):43–51.
3. Lenney W (2012) Asthma in children. Medicine 40;5:238–242.
4. From the Global Strategy for Asthma Management and Prevention, Global
Initiative for Asthma (GINA) (2011) Available: http://www.ginasthma.org.
5. Jeffery PK (2001) Remodeling in asthma and chronic obstructive lung diseases.
Am J Respir Crit Care Med 164(10 Pt2):S28–38.
6. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, et al. (2008) Stability of
asthma control with regular treatment: an analysis of the Gaining Optimal
Asthma controL (GOAL) study. Allergy 63(7):932–938.
7. Holgate ST (2010) A look at the pathogenesis of asthma: the need for a change
in direction. Discov Med 9(48):439–447.
8. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM (2000) Asthma.
From bronchoconstriction to airways inflammation and remodeling. Am J Respir
Crit Care Med 161(5):1720–1745.
9. Holgate ST (2007) Epithelium dysfunction in asthma. J Allergy Clin Immunol
120(6):1233–1244.
10. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, et al. (2011)
Defective epithelial barrier function in asthma. J Allergy Clin Immunol 128:549–
556.
11. Holgate ST, Davies DE (2009) Rethinking the pathogenesis of asthma.
Immunity 31(3)362–367.
Figure 8. TEER values of PBEC(N) and PBEC(A) under stimulation with IL-9, IL-9/IL-13 combination and IL-13. Values are expressed as
mean (error bar represents 1 SD) (straight line depicts analysis over Time; barred line depicts analysis between Clinical (Normal versus Asthmatic)). (A)
TEER values between PBEC(N) and PBEC(A) displayed no significant differences under unstimulated conditions over time, between clinical phenotype
(Normal versus Asthmatic) or by interaction (ie/. does PBEC(A) behave differently from PBEC(N) over time). (B) TEER values under stimulation with IL-9
demonstrated a significant reduction between PBEC(N) and PBEC(A) over time (Time p= 0.04) and between clinical (Clinical p = 0.03), however not by
interaction (Interaction p= 0.09). (C) TEER values under stimulation with IL-9/IL-13 combination demonstrated a significant reduction between
PBEC(N) and PBEC(A) over time (Time p=0.02) and between clinical (Clinical p = 0.005), however not by interaction (Interaction p= 0.7). (D) TEER
values under stimulation with IL-13 demonstrated a significant reduction between PBEC(N) and PBEC(A) over time (Time p= 0.01) and between
clinical (Clinical p = 0.0004), however not by interaction (Interaction p= 0.4).
doi:10.1371/journal.pone.0061023.g008
IL-9 Effects on a Bronchial Epithelial Cell Model
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e61023
12. Xing J, Wu Y, Ni B (2011) Th9: a new player in asthma pathogenesis? J Asthma
48(2):115–25.
13. Zhou Y, McLane M, Levitt R (2001) Th2 cytokines and asthma. IL-9 as a
therapeutic target for asthma. Resp Res 2:80–84.
14. Nicolaides N, Holroyd K, Ewart S, Eleff S, Kiser M, et al. (1997) Interleukin 9: a
candidate gene for asthma. Proc Natl Acad Sci USA 94:13175–13180.
15. Longphre M, Li D, Gallup M, Ordonez C, Redman T, et al. (1999) Allergen-
induced IL-9 directly stimulates mucin transcription in respiratory epithelial
cells. J Clin Invest 104:1375–1382.
16. Temann U, Laouar Y, Eynon E, Homer R, Flavell R (2007) IL-9 leads to airway
inflammation by inducing IL-13 expression in airway epithelial cells. Int
Immunol 19:1–10.
17. Xiang J, Rir-Sim-Ah J, Tesfaigzi Y (2008) IL-9 and IL-13 induce mucous cell
metaplasia that is reduced by IFN-gamma in a Bax-mediated pathway.
Am J Respir Cell Mol Biol 38:310–317.
18. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, et al. (2011) Safety
profile and clinical activity of multiple subcutaneous doses of MED-528, a
humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a
studies in subjects with asthma. BMC Pulm Med 28;11:14.
19. Vermeer P, Harson R, Einwalter L, Moninger T, Zabner J (2003) Interleukin-9
induces goblet cell hyperplasia during repair of human airway epithelia.
Am J Respir Cell Mol Biol 28:267–270.
20. Pezzulo AA, Starner TD, Scheetz TE, Traver GL, Tilley AE, et al. (2011). The
air-liquid interface and use of primary cell cultures are important to recapitulate
the transcriptional profile of in vivo airway epithelia. Am J Physiol Lung Cell
Mol Physiol 300(1):L25–31.
21. Haitchi HM, Davies DE, Holgate ST, Howarth PH, Whitsett JA (2011) The
SPDEF network regulates mucus cell differentiation in asthma [abstract].
Am J Respir Crit Care Med 183:A2771.
22. Wadsworth SJ, Atsuta R, McIntyre JO, Hackett T-L, Singhera GK, et al. (2010)
IL-13 and Th2 cytokine exposure triggers matrix metalloproteinase 7-mediated
Fas ligand cleavage from bronchial epithelial cells. J Allergy Clin Immunol
126:366–374.
23. Doherty GM, Christie SN, Skibinski G, Puddicombe SM, Warke TJ, et al.
(2003) Non-bronchoscopic sampling and culture of bronchial epithelial cells in
children. Clin Exp Allergy 33:1221–1225.
24. Parker J, Sarlang S, Thavagnanam S, Williamson G, O’Donoghue D, et al.
(2010) A 3-D well-differentiated model of paediatric bronchial epithelium
demonstrates unstimulated morphological differences between asthmatic and
non-asthmatic cells. Ped Res 67:17–22.
25. Thavagnanam S, Parker JC, Skibinski G, Mc Brien ME, Heaney LG, et al.
(2011) Effects of Interleukin-13 on mucociliary differentiation of paediatric
asthmatic bronchial epithelial cells. Ped Res 69(2):95–100.
26. Coyle PV, Ong GM, O’Neill HJ, McCaughey C, De Ornellas D, et al. (2004) A
touchdown nucleic acid amplification protocol as an alternative to culture
backup for immunofluorescence in the routine diagnosis of acute viral
respiratory tract infections. BMC Microbiol 4:41.
27. Gray TE, Guzman K, Davis CW, Abdullah LH, Nettesheim P (1996)
Mucociliary differentiation of serially passaged normal human tracheobronchial
epithelial cells. Am J Respir Cell Mol Biol 14:104–112.
28. Fulcher ML, Gabriel S, Burns KA, Yankaskas JR, Randell SH (2005) Well-
differentiated human airway epithelial cell cultures. Methods Mol Med 107:183–
206.
29. Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, et al. (1999)
Epidermal growth factor system regulates mucin production in airways. Proc
Natl Acad Sci USA 96:3081–3086.
30. Thomas B, Rutman A, Hirst R, Haldar P, Wardlaw AJ, et al. (2010) Ciliary
dysfunction and ultrastructural abnormalities are features of severe asthma.
J Allergy Clin Immunol 126:722–729.
IL-9 Effects on a Bronchial Epithelial Cell Model
PLOS ONE | www.plosone.org 11 May 2013 | Volume 8 | Issue 5 | e61023
